Loading clinical trials...
Loading clinical trials...
The main objective of this study is to assess the safety and tolerability of crinecerfont in pediatric participants 3 months to \<4 years of age with CAH.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Neurocrine Biosciences
NCT07473804 · Neonatal Salt Loss, Congenital Adrenal Hyperplasia (CAH)
NCT06573723 · Rare Diseases, Amyloidosis, and more
NCT06712823 · Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia
NCT03760835 · Congenital Adrenal Hyperplasia
NCT06754423 · Congenital Adrenal Hyperplasia
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions